XBRANE.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	11.59M
平均成交量	22.63M
市值	324.59M
EPS	SEK0 ( 2024-02-26 )
下一个收益日期	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.170
ATR14	SEK0.00100 (0.47%)

音量相关性

長: -0.07 (neutral)

短: -0.92 (very strong negative)

Signal:(39.878) Neutral

Xbrane Biopharma AB 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Xbrane Biopharma AB 相关性 - 货币/商品

0.00
( neutral )

Xbrane Biopharma AB 财务报表

Annual	2023
营收:	SEK238.73M
毛利润:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2023
营收:	SEK238.73M
毛利润:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

FY	2022
营收:	SEK57.62M
毛利润:	SEK41.04M (71.23 %)
EPS:	SEK-0.760

FY	2021
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-7.98

Financial Reports:

No articles found.

Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.